Genistein in Preventing Cardiometabolic Dysfunction in Patients with Prostate Cancer Undergoing Androgen Deprivation Therapy
This phase II trial studies genistein in preventing or reducing diabetes (blood sugar), heart, or blood vessels disease (cardiometabolic dysfunction) in patients with prostate cancer undergoing androgen deprivation therapy. Androgen is a male hormone that binds to androgen receptors inside the cancer cells, which causes the cancer cells to grow. Antiandrogen therapy or androgen deprivation therapy prevents this from happening. Despite the benefits of antiandrogen therapy, it is associated with an increased risk of cardiovascular dysfunction, such as high blood sugar and/or high cholesterol. Genistein is a natural supplement that comes from soy that in studies has been shown to decrease blood glucose and cholesterol, and it may prevent or reduce cardiometabolic dysfunction in patients receiving androgen deprivation therapy.